(Circulation. 1999;100:1102-1108.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Treatment of Experimental Viral Myocarditis With Interleukin-10
From the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, and the Department of Internal Medicine, Utano National Hospital (H.I.), Kyoto, Japan.
Correspondence to Akira Matsumori, MD, PhD, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606, Japan. E-mail amat{at}kuhp.kyoto-u.ac.jp
Background—The T helper cell type 2–associated cytokine interleukin (IL)-10 has a variety of immunomodulatory properties. However, the effects of the cytokine on viral myocarditis remain unclear.
Methods and Results—We studied the effects of recombinant human
IL-10 (rhIL-10) fully active on mouse cells in a murine experimental
model of acute viral myocarditis caused by the encephalomyocarditis
virus (EMCV). Four-week-old DBA/2 mice were inoculated with EMCV (day
0). rhIL-10 (10 µg/mouse) was administered once daily, starting on
day 0, and control mice received vehicle only. Survival rates were
determined on day 14. Myocardial histopathology, cytokine
levels in the heart by ELISA assay, and myocardial virus concentration
were examined on day 6, and the expression levels of myocardial
inducible nitric oxide synthase (iNOS) mRNA were measured by
competitive polymerase chain reaction. The 14-day survival in mice
treated with rhIL-10 was significantly higher (80%) than in the
control group (30%, n=10 in each, P<0.05). rhIL-10
treatment significantly attenuated myocardial lesions and suppressed
tumor necrosis factor-
and IL-2 in the heart. rhIL-10 treatment had
little effect on myocardial virus concentration. The expression levels
of myocardial iNOS mRNA were significantly decreased in the group
treated with rhIL-10 (8.6±4.7 amol/mg total RNA in treated versus
26.5±7.1 amol/mg total RNA in control mice,
P<0.05).
Conclusions—These findings provide new insights into the in vivo effects of IL-10 on viral infection and suggest a therapeutic effect of IL-10 on viral myocarditis.
Key Words: interleukins • myocarditis • tumor necrosis factor • nitric oxide synthase
This article has been cited by other articles:
 |
|
 |
|
  C. Stumpf, K. Seybold, S. Petzi, G. Wasmeier, D. Raaz, A. Yilmaz, T. Anger, W. G. Daniel, and C. D. Garlichs Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction Eur J Heart Fail, August 1, 2008; 10(8): 733 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gelderblom, J. Schmidt, D. Londono, Y. Bai, J. Quandt, R. Hornung, A. Marques, R. Martin, and D. Cadavid Role of Interleukin 10 during Persistent Infection with the Relapsing Fever Spirochete Borrelia turicatae Am. J. Pathol., January 1, 2007; 170(1): 251 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Szalay, M. Sauter, J. Hald, A. Weinzierl, R. Kandolf, and K. Klingel Sustained Nitric Oxide Synthesis Contributes to Immunopathology in Ongoing Myocarditis Attributable to Interleukin-10 Disorders Am. J. Pathol., December 1, 2006; 169(6): 2085 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Wang, A. Meissner, S. Malek, Y. Chen, Q. Ke, J. Zhang, V. Chu, T. G. Hampton, C. S. Crumpacker, W. H. Abelmann, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1577 - H1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fuse, M. Kodama, Y. Okura, M. Ito, K. Kato, H. Hanawa, and Y. Aizawa Short-term prognostic value of initial serum levels of interleukin-10 in patients with acute myocarditis Eur J Heart Fail, January 1, 2005; 7(1): 109 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishii, T. Inomata, H. Takehana, I. Takeuchi, H. Nakano, T. Koitabashi, J.-i. Nakahata, N. Aoyama, and T. Izumi Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1292 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Matsumori, Y. Nunokawa, A. Yamaki, K. Yamamoto, M.-W. Hwang, T. Miyamoto, M. Hara, R. Nishio, K. Kitaura-Inenaga, and K. Ono Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-{kappa}B inhibitor Eur J Heart Fail, March 1, 2004; 6(2): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, T. Shioi, K. Uchiyama, T. Miyamoto, S. Sasayama, and A. Matsumori Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice J. Am. Coll. Cardiol., December 3, 2003; 42(11): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nishio, T. Shioi, S. Sasayama, and A. Matsumori Carvedilol increases the production of interleukin-12 and interferon-{gamma} and improves the survival of mice infected with the encephalomyocarditis virus J. Am. Coll. Cardiol., January 15, 2003; 41(2): 340 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Matsumori Cytokines in myocarditis and dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I42 - I45. [Abstract] [PDF]
|
|
|
|
|
|
R. Nishio, S. Sasayama, and A. Matsumori Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1506 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kaya, K. M. Dohmen, Y. Wang, J. Schlichting, M. Afanasyeva, F. Leuschner, and N. R. Rose Cutting Edge: A Critical Role for IL-10 in Induction of Nasal Tolerance in Experimental Autoimmune Myocarditis J. Immunol., February 15, 2002; 168(4): 1552 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Watanabe, M. Nakazawa, K. Fuse, H. Hanawa, M. Kodama, Y. Aizawa, T. Ohnuki, F. Gejyo, H. Maruyama, and J.-i. Miyazaki Protection Against Autoimmune Myocarditis by Gene Transfer of Interleukin-10 by Electroporation Circulation, September 4, 2001; 104(10): 1098 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Henke, R. Zell, G. Ehrlich, and A. Stelzner Expression of Immunoregulatory Cytokines by Recombinant Coxsackievirus B3 Variants Confers Protection against Virus-Caused Myocarditis J. Virol., September 1, 2001; 75(17): 8187 - 8194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miyamoto, A. Matsumori, M.-W. Hwang, R. Nishio, H. Ito, and S. Sasayama Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Exley, N. J. Bigley, O. Cheng, S. M. A. Tahir, S. T. Smiley, Q. L. Carter, H. F. Stills, M. J. Grusby, Y. Koezuka, M. Taniguchi, et al. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus J. Leukoc. Biol., May 1, 2001; 69(5): 713 - 718. [Abstract] [Full Text]
|
|
|
|
 |
|
 M T Kearney, J M Cotton, P J Richardson, and A M Shah Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management Postgrad. Med. J., January 1, 2001; 77(903): 4 - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Hamanaka, Y. Saito, H. Yasukawa, I. Kishimoto, K. Kuwahara, Y. Miyamoto, M. Harada, E. Ogawa, N. Kajiyama, N. Takahashi, et al. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 Is Involved in gp130 Resistance in Cardiovascular System in Rat Treated With Cardiotrophin-1 In Vivo Circ. Res., April 13, 2001; 88(7): 727 - 732. [Abstract] [Full Text] [PDF]
|
|